Despite these drugs improving cognitive performance in AD, the development of the disease remains unaddressed, and further research is focused on targeted therapeutics for neurodegenerative diseases involving the Aβ, Tau, and cholinergic systems (Pardo-Moreno et al., 2022; Ornish et al., 2024; Razzaghi et al., 2024). This evidence concerns the gene MAPT and Alzheimer disease.